This ETF Owns 3,500 Stocks, Is It Better Than the S&P 500?
Vanguard’s Extended Market ETF (VXF) is a broad fund made up of thousands of stocks across essentially every part of the American business landscape. Like many ETFs, VXF attempts to give investors access to a broad selection of stocks without the difficulty and risk involved in picking individual companies.
Today, let’s take a deeper look at VXF to see if the fund is a good investment at the moment. » Read more about: This ETF Owns 3,500 Stocks, Is It Better Than the S&P 500? »
Read More
Spotlight: Time To Buy Vaccine Manufacturer Before Winter?
It’s impossible to discuss Moderna without mentioning its COVID-19 vaccine, which propelled the stock to record highs in 2021 approaching $500 per share. However, slower sales caused the stock to plunge by almost 80%.
Second-quarter reports in 2023 show a net loss of $1.38 billion, a stark contrast to the net income of $5.4 billion in Q4 2021.
» Read more about: Spotlight: Time To Buy Vaccine Manufacturer Before Winter? »
Read More
Market Commentary: Is This 7.9% Dividend Real?
In my view, Verizon’s generous dividend isn’t just stable, it’s on track to climb even higher. As it stands, Verizon offers a tantalizing dividend yield of 7.9%, a figure amplified by the recent dip in its stock price. The stock has lost about a fifth of its value from its peak over the past 52 weeks,
» Read more about: Market Commentary: Is This 7.9% Dividend Real? »
Read More
Spotlight: 1 Gene Editing Stock Set To Skyrocket
Cathie Wood has been investing heavily in Verve Therapeutics (VERV), a company developing therapies for cardiovascular diseases. So what’s all the fuss about? We took a deeper dive to find out.
Read More
Palantir’s Path to $10 Billion: Can This AI Giant Keep Growing?
Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown into a phase of reaccelerating revenue and improving profitability in 2024-2025. After a modest ~17% revenue growth in 2023, Palantir’s top-line expanded by 29% in 2024 to $2.87 billion, buoyed by rising demand for its data analytics and AI platforms.
The company also achieved GAAP profitability,
» Read more about: Palantir’s Path to $10 Billion: Can This AI Giant Keep Growing? »
Read MoreThe Burst
How a $300 Mistake Opened a $1 Billion Market
Novo Nordisk, the pharmaceutical giant behind weight-loss blockbusters Ozempic and Wegovy, just let a key patent on semaglutide lapse in Canada because it forgot to pay a routine maintenance fee, the pharmaceutical equivalent of forgetting to renew your car registration.
As a result, generic versions of semaglutide, the active ingredient in both drugs,
» Read more about: How a $300 Mistake Opened a $1 Billion Market »
Read MoreThe Ivy
Is AppLovin Still a Buy After Its Incredible Run?
AppLovin (NASDAQ: APP) has had the kind of year investors dream about. The mobile app marketing and advertising platform, best known for its strength in mobile gaming has seen its stock rocket more than 5x over the past 12 months, fueled by relentless revenue growth and eye-popping profits.
With a move that big,
» Read more about: Is AppLovin Still a Buy After Its Incredible Run? »
Read MoreThe Daily
Canadian Energy Companies Are Outperforming Despite Weak Oil Prices
Recently, we have noted that U.S. investors are increasingly buying Canadian Oil & Gas companies, even as global oil prices move lower. According to McCrea, U.S. funds now own about 59% of Canadian oil and gas companies, up from 56% at the end of 2024, while investments by Canadians have declined to 34% from 37%.
» Read more about: Canadian Energy Companies Are Outperforming Despite Weak Oil Prices »